Cancers with a high mutation burden, including Hodgkin's lymphoma, melanoma, renal cell carcinoma, nonsmall cell lung cancer, and urinary tract epithelial bladder cancer, show promising response rates to anti-PD-1/PD-L1 antibody therapy [20–24]. This evidence concerns the gene CD274 and Hodgkins lymphoma.